Serotype replacement in disease after pneumococcal vaccinationArchived
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine
Weinberger DM, Malley R, Lipsitch M. Lancet 2011; 378: 1962–73.
The recently introduced 13-valent vaccine has the potential to have significant and sustained effects on disease, particularly in developing countries. Serotypes 1 and 5, in particular, which are covered by this vaccine, are rarely carried but cause a lot of disease in many areas.
As a result, the elimination of these two specific serotypes is unlikely to be followed by substantial replacement. Although it is difficult to predict how the composition of NVTs will change after the introduction of PCV13, projections based on the invasiveness of the serotypes suggest that this new vaccine will result in additional reductions in disease incidence.
Decline in early childhood respiratory tract infections in the norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccinationArchived
27 Nov 2012 - The study design and analysis controlled for influence of potentially confounding trends, such as improvement of day-care carriage and decreasing prevalence of smoking during the study period.
A review of the effect of immunization programs on antimicrobial utilizationArchived
16 Oct 2012 - Antimicrobial stewardship policies are increasingly being implemented as a measure to prevent and control antimicrobial resistance.
Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in childrenArchived
16 Aug 2012 - The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.